Analyst in Laboratory Biomedicine, Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Slovenia
BIOGRAPHY
Date: November 9, 2022 Time: 3:00am (PDT), 6:00am (EDT), 12:00pm (CET)
How to improve patient management with molecular solutions for cervical cancer screening and CIN2/3 diagnosed women
Speakers
-
Wieke Kremer
Resident Obstetrics and Gynaecology, OLVGBIOGRAPHY
Event Date & Time
Date: November 9, 2022
Time: 3:00am (PDT), 6:00am (EDT), 12:00pm (CET)
Abstract
An increasing number of cervical cancer screening programs are converting from cytology to primary HPV-based organized screening because of better clinical performance. HPV assays need to be clinically validated and comply with international guidelines to assure high quality of primary HPV-based screening.
Nevertheless screening also results in considerable overtreatment because many CIN2/3 lesions show spontaneous regression so a triage strategy is necessary and methylation can be used to support a wait-and-see policy in women with CIN2/3.
The webinar brings recent study data about the fully automated clinically approved NeuMoDx HPV Test Strip screening test and the prognostic value of FAM19A4/miR124-2 methylation to support conservative management of CIN2+ diagnosed women.
Webinars will be available for unlimited on-demand viewing after live event.
You May Also Like
DEC 10, 2024 | 9:00 AM
To-date, proteomic analysis has been severely limited in scale and resolution. Analyzing protein samples using an intact, single-molecule approach holds th...
OCT 02, 2024 | 7:30 AM
De novo gene synthesis and protein expression are established technologies that can give access to nearly any target DNA or protein sequence, allowing for engineering of biologics. In this p...
Loading Comments...